Voy Weight Loss UK Review: Cost, Safety & Results (2026)

Published on: May 5, 2026

Medically reviewed by

Ashis Tandukar

Superintendent Pharmacist · Reg: GPhC No. 2084170

If you've spent any time researching weight loss injections in the UK over the past year, you've probably seen Voy's ads. They're hard to miss — the bright yellow branding, the £94 starter price, the chief medical officer's smiling face. Voy has grown faster than almost any GLP-1 provider in the UK, and the question we hear in clinic most often now is: "Is Voy any good?"

The honest answer takes a few minutes to unpack. Voy gets some things right and other things less so, and a December 2025 ruling from the medicines regulator added a wrinkle worth understanding before you sign up.

What Voy actually is

Voy is the weight-loss arm of Manual, a London-based digital health company founded in 2018 that originally specialised in men's hair loss and erectile dysfunction. Manual launched Voy as a separate sub-brand in 2024 to tap into the GLP-1 boom, and it scaled quickly — over 100,000 members signed up within the first 18 months.

The model is familiar to anyone who's used a GLP-1 service. You complete an online consultation, a clinician reviews your eligibility, the medication ships to your door, and you have ongoing access to a health coach and clinical team via the Voy app. There's an AI assistant called Joy for routine questions, food and progress tracking built in, and add-on blood testing through Voy's Do Health platform.

What sets Voy apart from most competitors isn't the model itself — it's how aggressively they've priced and marketed it. The £94 starter price for Mounjaro is among the cheapest in the UK, and the 10% weight-loss guarantee is unique among the major providers.

What you actually pay

Voy's headline price applies to the lowest Mounjaro dose (2.5 mg) and goes up at each titration step. A rough guide based on current Voy pricing:

Wegovy is also available, with similar but slightly different price tiers. Saxenda and Orlistat sit further down the price range. Prices have shifted over the past year as Eli Lilly's price increases worked their way through to consumers — for the latest figures across providers, our Mounjaro UK cost guide tracks the going rates.

A few practical notes on Voy's pricing. There are no separate consultation or follow-up fees — the monthly subscription includes the medication, clinician oversight and coach access. Discounts are available if you commit to longer plans (3, 6 or 12 months). Cancellation is straightforward through the app. And shipping is included; pens arrive in cold packaging within a few days.

What medications they prescribe

Voy offers four weight-loss medications — a wider menu than most competitors:

• Mounjaro (tirzepatide) — their flagship, dual GLP-1/GIP weekly injection
• Wegovy (semaglutide) — the established GLP-1-only weekly injection
• Saxenda (liraglutide) — an older daily GLP-1 injection
• Orlistat (sold as Orlos) — the daily fat-blocker capsule

For most people seeking serious weight loss, the choice in clinic is between Mounjaro and Wegovy — we've covered the differences in our existing comparison piece. Saxenda is now an unusual choice; daily injections are harder to stick with and the weight-loss data is weaker than the weekly options. Orlistat works through a completely different mechanism and tends to be reserved for people who can't or don't want to use injections.

The evidence Voy actually has

This is where things get interesting. Voy publishes some impressive numbers on their site:

• "97% of patients felt their overall health had improved"
• "Patients lost 5 times more weight with Voy than with diet and exercise alone"
• "Voy members on Mounjaro lose up to 21.5% by month 12"

The 21.5% figure comes from an internal analysis of around 58,000 Voy members on Mounjaro, conducted in partnership with researchers at Imperial College London. It's a substantial dataset, and the academic partnership is credible.

The caveat: the analysis hasn't yet been published in a peer-reviewed journal. That distinction matters. Peer review is the process by which independent experts pressure-test a study's methodology — how the cohort was selected, how dropouts were handled, whether the comparison group was fair, whether the headline number is statistically meaningful. None of that has happened publicly with the Voy data.

For comparison, the SURMOUNT-1 randomised controlled trial of Mounjaro — published in the New England Journal of Medicine — showed an average weight loss of 22.5% at 72 weeks. Voy's 21.5% over 10 months is broadly consistent with the trial data, which is reassuring. But "broadly consistent" isn't the same as "validated."

The MHRA advertising ruling: what happened

In December 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) reviewed a sponsored social media advertisement run by Menwell Ltd (Voy's parent company) and ruled that it didn't comply with UK medicines advertising rules.

The advert in question promoted Orlos (orlistat) — an over-the-counter pharmacy medicine — using statements like "They raised prices unexpectedly — we lowered ours on purpose" and "Start from £94 a month for the same medication." It featured the chief medical officer's image and signature, and contained links to information about prescription-only weight-loss medications.

The MHRA's specific concerns:

• The price references were misleading and didn't appear to relate to the over-the-counter product being advertised
• There was implied endorsement of the product by a healthcare professional, which UK rules don't allow for medicines
• The links in the ad effectively presented promotional information about prescription-only medicines (POMs), which is prohibited under UK law — POMs cannot be advertised to the general public

Voy's parent company disagreed with the assessment but withdrew the advertisement and confirmed that future advertising would comply with the Human Medicines Regulations and the MHRA Blue Guide.

It's worth being clear about what this ruling does and doesn't mean. It doesn't suggest Voy's medical service is unsafe, that their clinicians aren't qualified, or that the medication is counterfeit. The MHRA was looking at one specific advert and how it complied with marketing rules. Plenty of other UK providers have had similar rulings against them over the years — these advertising regulations are strict by design, because the danger of consumers self-medicating with prescription weight-loss drugs is real.

What it does suggest is that the marketing has, at times, pushed harder than the regulations allow. If you're choosing between providers and you care about strict regulatory compliance — particularly around how medications are advertised — this is information worth having.

How the support compares

Voy's clinical team is led by chief medical officer Dr Earim Chaudry. Members get access to a personal health coach, the broader clinical team for prescribing and monitoring, and the AI assistant Joy for routine questions. Communication is app-based.

What Voy publishes about their coaching staff is light on detail. The website refers to "health coaches" and "clinicians" without specifying particular regulatory registrations or qualifications for the coaches — whether they're registered dietitians, registered nutritionists, behavioural psychologists, or general health and fitness coaches. The clinical prescribers will be appropriately registered (UK law requires this), but the coaching layer sits in a less regulated space.

For comparison, services like Second Nature publicly detail HCPC- or AfN-registered dietitians supervising their coaching. heySlim's clinical team is led by GMC-registered doctors with structured handover and regular review. The model you prefer depends on what kind of support you actually want — some people thrive with a dedicated personal coach, others prefer doctor-led oversight with less frequent contact.

The 10% money-back guarantee

Voy is the only major UK GLP-1 provider offering a weight-loss guarantee: lose at least 10% of your starting body weight in six months, or get your money back. It's a confident claim and a useful selling point — but the terms are tighter than the headline suggests. A few things worth checking before you bank on it:

• The guarantee typically applies only if you stay on a continuous, paid 6-month plan with no breaks
• You usually need to attend scheduled coach check-ins and follow the prescribed dose escalation schedule
• Logging weight regularly through the app is normally required
• People who switch providers part-way through, pause treatment, or don't titrate to the prescribed dose will fall outside the guarantee
• Refunds tend to be capped at the medication subscription cost — they don't cover incidental costs

Read the small print before you commit, particularly if you're someone who responds slowly to GLP-1s or who has medical reasons for staying on a lower dose. The guarantee is real, but it's narrower than the marketing implies.

Trustpilot and the user experience

Voy has a Trustpilot rating of 4.7/5 from over 17,000 reviews, which is genuinely strong volume — only a handful of UK weight-loss services have that depth of feedback. Most positive reviews mention easy onboarding, fast medication delivery and responsive coach communication.

The negative reviews — and there are some, as with any service at scale — cluster around a few themes. Issues with faulty pens not being replaced. Difficulty getting hold of customer service when something goes wrong. Subscription cancellation friction. Inconsistent advice between coaches. None of these are unique to Voy, but the volume of complaints scales with membership size, so be aware before signing up that the experience can be variable.

Who Voy might be a good fit for

Based on what we've seen in clinic and what users report, Voy tends to suit people who:

• Want one of the cheapest entry points for Mounjaro in the UK
• Prefer app-first, asynchronous interaction over scheduled phone or video appointments
• Like the option of a wider medication menu (Saxenda and Orlistat alongside the injections)
• Are comfortable navigating digital tools and self-tracking
• Find the 6-month guarantee genuinely reassuring at the start

It's likely to be less of a fit if you:

• Want detailed transparency about the qualifications of every team member supporting you
• Prefer doctor-led oversight rather than coach-led check-ins
• Have complex medical history that warrants more in-depth clinical conversation
• Place a high premium on regulatory compliance in how a service markets itself
• Want peer-reviewed clinical research to underpin the support model

If you're weighing Voy against other options, our best Mounjaro provider in the UK guide compares them directly on price, clinical model and patient experience. The Juniper UK review is a useful read if you're specifically looking at the female-focused alternatives, and heySlim vs Bolt Pharmacy covers another popular comparison.

How to start (or switch) safely

If you decide to go with Voy, the process is straightforward: complete the online assessment, wait for clinical review, and your starter dose ships within a few days. Standard advice applies — start at the lowest dose, climb the ladder slowly, and don't ignore side effects that feel disproportionate.

If you're switching to Voy from another provider, leave at least 7 days between your last dose of the old medication and your first dose of the new one. If you're considering switching from Voy elsewhere, that same window applies. Our GLP-1 dose titration guide covers what to watch for at each step.

And as with any GLP-1 medication, never buy from anywhere outside a regulated UK pharmacy. Counterfeit Mounjaro and Wegovy have been seized in the UK, and the safety risk from a contaminated or wrongly dosed pen is real. Stick to MHRA-regulated providers — Voy included.

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting any treatment.